Early Onset Severe Hypertensive Disease in Pregnancy and Screening for Antiphospholipid Syndrome

Abstract

Objective Although preterm delivery (PTD) before 34 weeks for severe hypertensive disease is a diagnostic criterion for antiphospholipid syndrome (APS), there is no consensus regarding testing for antiphospholipid antibodies (aPL) in this setting. We aim to describe the frequency of and the characteristics associated with inpatient aPL testing in this population.

Study Design In this retrospective study of PTD before 34 weeks for severe hypertensive disease, charts were reviewed for aPL testing, gestational age at delivery, fetal complications, and severity of maternal disease. Wilcoxon rank-sum test, Fisher's exact, and chi-squared tests were used for analyses of continuous and categorical variables, and multivariate logistic regression for adjusted odds ratios.

Results Among 133 cases, 14.3% had APS screening via aPL testing. Screened patients delivered earlier than unscreened patients (28.9 vs. 31.7 weeks, p <0.001). Each additional week of gestation was associated with a 39% decrease in the odds of screening (95% confidence interval: 0.43–0.85). There were no other differences between the groups.

Conclusion APS screening after PTD for severe hypertensive disease is uncommon but more likely with earlier PTD. Despite conflicting recommendations from professional organizations, prior studies demonstrate contraceptive, obstetrical, and long-term risks associated with APS, suggesting that we should increase our screening efforts.

Keywords

antiphospholipid syndrome - preterm preeclampsia - antiphospholipid screening - severe hypertensive disease of pregnancy - antiphospholipid antibodies

Declaration of Interest

The authors report no conflicts of interest. There were no external funding sources for this study.

Note

This study was presented in poster format at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, Texas on Saturday, April 28, 2018.

• References

• 1 Wilson WA, Gharavi AE, Koike T. , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-1311
• 2 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 3 Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: antiphospholipid syndrome. Obstet Gynecol 2012; 120 (06) 1514-1521
• 4 National Collaborating Centre for Women's and Children's Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders during Pregnancy. London: Royal College Obstetricians and Gynaecologists; 2010
• 5 Royal College of Obstetricians and Gynaecologists. Green-Top Guideline Number 37a: Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. London: Royal College of Obstetricians and Gynaecologists; 2015
• 6 Royal College of Obstetricians and Gynaecologists. Faculty of Sexual and Reproductive Healthcare Statement on Venous Thromboembolism and Hormonal Contraception. London: Royal College of Obstetricians and Gynaecologists; 2014
• 7 Magee LA, Pels A, Helewa M. , et al for the Canadian Hypertensive Disorders of Pregnancy Working Group. Society of Obstetricians and Gynaecologists of Canada clinical practice guideline number 307: diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2014; 36 (05) 416-441
• 8 Chan WS, Rey E, Kent NE. , et al , for the VTE in Pregnancy Guideline Working Group; Society of Obstetricians and Gynaecologists of Canada; clinical practice guideline number 308 venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36 (06) 527-553
• 9 Lowe SA, Bowyer L, Lust K. , et al. Society of Obstetric Medicine of Australia and New Zealand guideline for the management of hypertensive disorders of pregnancy. Aust N Z Obstet Gynaecol 2015; 55 (05) e1-e329
• 10 American College of Obstetricians and Gynecologists. Practice bulletin 33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99 (01) 159-167
• 11 American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy: hypertension in pregnancy. Obstet Gynecol 2013 122. (05):
• 12 Gris JC, Bouvier S, Molinari N. , et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119 (11) 2624-2632
• 13 Lefèvre G, Lambert M, Bacri JL. , et al. Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus 2011; 20 (08) 861-865
• 14 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. ; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
• 15 Andreoli L, Bertsias GK, Agmon-Levin N. , et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76 (03) 476-485
• 16 Rodger MA, Gris JC, de Vries JIP. , et al; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388 (10060): 2629-2641
• 17 Erkan D, Aguiar CL, Andrade D. , et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13 (06) 685-696
• 18 Ruffati A, Tonello M, Hoxha A. , et al. Effect of additional treatments combined with conventional therapies in pregnancy patients with high-risk antiphospholipid syndrome: a multicenter study. Thromb Haemost 2018; 18: 639-646
• 19 Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016; 214 (02) 273.e1-273.e8
• 20 Schreiber K, Breen K, Cohen H. , et al. Hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43 (06) 562-571